课题基金 / 基金详情

The I-STRAT trial: Do Isolation Strategies reduce endemic levels of MRSA and Clostridium difficle associated diarrhoea

The I-STRAT trial: Do Isolation Strategies reduce endemic levels of MRSA and Clostridium difficle associated diarrhoea
I-STRAT 试验:隔离策略是否可以降低 MRSA 和艰难梭菌相关性腹泻的流行水平
批准号:
G0701815/1
负责人:
Sheldon Stone
金额:
$53.99万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2008
资助国家:
英国
项目状态:
已结题
起止时间:
2008 至 --

项目摘要

项目成果

Sheldon Stone的其他基金

相似基金

相关文献

中文摘要
翻译
大多数人害怕进医院的原因是什么?感染超级细菌,如MRSA或艰难梭菌!尽管政府采取了一系列举措来减少这些问题,但它们似乎很猖獗。当然,他们的控制应该很简单。让医院保持干净!确保员工洗手!立即将感染这些疾病的人隔离起来!然而,事实证明,这最后一次干预--孤立--是非常困难的。感染控制人员经常抱怨缺乏有效的隔离设施。管理人员表示,他们负担不起提供更多隔离床位的费用,特别是在没有来自适当试验的良好证据来证明这一点的情况下。这项研究将彻底解决提供有效隔离的困难。它将通过全国范围的咨询和与25-30家信托基金的密集工作,帮助信托基金在组织和个人层面消除有效孤立的障碍。它将帮助他们想出如何使隔离设施可用,并最大限度地利用他们拥有的这些设施的想法。信托公司将能够设计他们认为最有可能奏效的隔离政策,一小部分人会吗?试驾?这是一项初步试验,随后可以推广到更多的医院,以找到通过隔离来减少耐甲氧西林金黄色葡萄球菌和艰难梭菌的最佳方法。I-strat试验的两位主要研究人员巴里·库克森和谢尔顿·斯通说?世界上没有任何地方研究过如何最好地进行隔离。这其中的部分原因是,对此进行适当的审判有太多的困难。人们认为隔离可能很昂贵,或者很难提供指定的工作人员。甚至没有人确切知道哪些患者应该被隔离,或者我们应该如何衡量成功。这项研究将解决这些问题,与信托基金密切合作,帮助他们提出自己的干预措施,以设计一项可行的迷你试验。如果这看起来可行,那么我们可以进行一项全面的试验,这可能会为我们提供一些明确的答案,说明隔离在对抗这些所谓的超级细菌方面的作用?
英文摘要
What do most people fear about coming into hospital? Catching a superbug infection such as MRSA or Clostridium difficile! Despite a tranche of Government initiatives to reduce these, they appear rampant. Surely their control should be simple. Keep the hospitals clean! Make sure staff clean their hands! Put people with these infections into isolation straight away! However, it is this last intervention , isolation, that proves so difficult. Infection Control staff often bemoan the lack of effective isolation facilities. Managers say they cannot afford to make more isolation beds available, especially as there is no good evidence from a proper trial to prove this works. This study will get to the bottom of the difficulties in providing effective isolation. It will help Trusts, through a nationwide consultation, and intensive work with 25-30 trusts, to work out the barriers, at organizational and individual levels, to effective isolation. It will help them come up with ideas of how to make isolation facilities available and make the most of those facilities that they have. Trusts will be able to design the isolation policies they think most likely to work, a small number will ?test drive? these in a preliminary trial that can then be rolled out to a larger number of hospitals, to find the best way to reduce MRSA and Clostridium difficile through isolation.The two lead researchers in the I-STRAT trial, Barry Cookson and Sheldon Stone, say ?Nowhere in the world has looked at how best to make isolation work. Part of the reason for that is that there are so many difficulties in running a proper trial of this. People think that isolation may be expensive, or that is it hard to provide designated staff. No one is even sure exactly which patients should be isolated, or how we should measure success. This study is going to address these issues, working closely with Trusts, to help them come up with their own interventions to design a feasible ?mini-trial?. If that looks practical, then we could move to a full scale trial which might provide us with some definite answers about the role of isolation in fighting these so-called ?superbugs?
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intensity Frontier Physics Studies with b and c Quarks at LHCb
  • 批准号:
    1507572
  • 项目类别:
    Continuing Grant
  • 资助金额:
    $319.5万
  • 财政年份:
    2015
  • 负责人:
    Sheldon Stone
  • 依托单位:
MRI: Development of a Radiation Tolerant Low-mass Silicon Tracker for the LHCb Upgrade
  • 批准号:
    1337127
  • 项目类别:
    Standard Grant
  • 资助金额:
    $39.69万
  • 财政年份:
    2013
  • 负责人:
    Sheldon Stone
  • 依托单位:
Research at the Intensity Frontier with the LHCb Experiment
  • 批准号:
    1201974
  • 项目类别:
    Continuing Grant
  • 资助金额:
    $304.0万
  • 财政年份:
    2012
  • 负责人:
    Sheldon Stone
  • 依托单位:
Flavor Physics and CP Violation 2009
  • 批准号:
    0841178
  • 项目类别:
    Standard Grant
  • 资助金额:
    $0.8万
  • 财政年份:
    2009
  • 负责人:
    Sheldon Stone
  • 依托单位:
国内基金
海外基金
基于移动健康技术干预动脉粥样硬化性心血管疾病高危人群的随机对照现场试验:The ASCVD Risk Intervention Trial
  • 批准号:
    81973152
  • 项目类别:
    面上项目
  • 资助金额:
    54.0万元
  • 批准年份:
    2019
  • 负责人:
    胡东生
  • 依托单位: